100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44CA192435
Award Date
9/1/15
Completion Date
8/31/22
Dollars Obligated
$6.2M
Overview
Activity
11
Transactions
11
Subawards
Similar Awards
Federal Agency
National Cancer Institute
Awardee
Celldex Therapeutics, Inc. (EGSNNDJBMAG5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Update #1
Update #2
IMMUNE MODULATION OF RADIATION THERAPY WITH FLT3 LIGAND
Posted 8/19/15
5
1
2
3
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
IMMUNE MODULATION OF RADIATION THERAPY WITH FLT3 LIGAND - PROJECT SUMMARY THIS PROPOSAL IS A UNIQUE COLLABORATION BETWEEN A SMALL, BUT FULL CAPABILITY BIOTECHNOLOGY COMPANY AND AN ACADEMIC INSTITUTION SPECIALIZED IN RADIATION THERAPY. STEREOTACTIC RADIOSURGERY (SRS) IS BEING FREQUENTLY USED TO CONTROL MACROSCOPIC TUMOR IN PATIENTS WITH LIMITED METASTASES. THE SUCCESS OF SRS IN CONTROLLING MACROSCOPIC DISEASE HAS GENERATED ENTHUSIASM IN COMBINING SRS WITH SYSTEMIC AGENTS, SUCH AS, CYTOTOXIC CHEMOTHERAPEUTICS AND BIOLOGICALLY TARGETED AGENTS FOR THE TREATMENT OF EARLY METASTATIC CANCER. THE GOAL IS TO TREAT MACROSCOPIC TUMOR WITH SRS WHILE SYSTEMIC CHEMOTHERAPY TARGETS MICROSCOPIC CANCER CELLS. AMONG SYSTEMIC THERAPEUTICS, IMMUNOTHERAPY HAS THE POTENTIAL TO BE INTEGRATED WITH RT TO INDUCE A TUMOR-SPECIFIC IMMUNE RESPONSE THAT COULD ENABLE THE BODY'S OWN IMMUNE SYSTEM TO TARGET RESIDUAL AND METASTATIC TUMOR CELLS THAT ARE NOT ABLATED AFTER RADIATION THERAPY ALONE. SINCE RADIATION THERAPY RESULTS IN THE RELEASE OF TUMOR ASSOCIATED ANTIGENS FROM THE DYING TUMOR CELLS, INCREASING THE NUMBER AND ACTIVITY OF PROFESSIONAL ANTIGEN PRESENTING CELLS SUCH AS DENDRITIC CELLS COULD INCREASE THE INDUCTION OF EFFECTIVE TUMOR IMMUNITY. WE HAVE SHOWN THAT ADMINISTRATION OF FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L) SIGNIFICANTLY INCREASES IN THE NUMBER OF DENDRITIC CELLS AND SYNERGIZES WITH RADIATION THERAPY TO IMPROVE SURVIVAL IN PRECLINICAL MODELS OF LUNG CANCER AND IN PRELIMINARY RESULTS FROM A PILOT HUMAN TRIAL OF PATIENTS WITH NON-SMALL CELL LUNG CANCER. THIS PROPOSAL AIMS TO BROADEN THESE EXCITING FINDINGS BY EXPANDING THE CLINICAL EXPERIENCE TO MOVE THE THERAPY TOWARDS COMMERCIALIZATION FOR GREATER PATIENT ACCESS. THE PROPOSAL ALSO INCLUDES INTRODUCTION INTO THE CLINICAL TRIAL OF A DENDRITIC CELL ACTIVATING ANTIBODY THAT TARGETS CD40, A PATHWAY THAT HAS BEEN SHOWN TO SYNERGIZE WITH FLT3L AND RADIATION THERAPY. TO SUPPORT THE CLINICAL STUDY, CLINICAL GRADE FLTR3L AND THE CD40 AGONIST ANTIBODY WILL BE MANUFACTURED.
($1m)
4/28/23
Not listed
IMMUNE MODULATION OF RADIATION THERAPY WITH FLT3 LIGAND - PROJECT SUMMARY THIS PROPOSAL IS A UNIQUE COLLABORATION BETWEEN A SMALL, BUT FULL CAPABILITY BIOTECHNOLOGY COMPANY AND AN ACADEMIC INSTITUTION SPECIALIZED IN RADIATION THERAPY. STEREOTACTIC RADIOSURGERY (SRS) IS BEING FREQUENTLY USED TO CONTROL MACROSCOPIC TUMOR IN PATIENTS WITH LIMITED METASTASES. THE SUCCESS OF SRS IN CONTROLLING MACROSCOPIC DISEASE HAS GENERATED ENTHUSIASM IN COMBINING SRS WITH SYSTEMIC AGENTS, SUCH AS, CYTOTOXIC CHEMOTHERAPEUTICS AND BIOLOGICALLY TARGETED AGENTS FOR THE TREATMENT OF EARLY METASTATIC CANCER. THE GOAL IS TO TREAT MACROSCOPIC TUMOR WITH SRS WHILE SYSTEMIC CHEMOTHERAPY TARGETS MICROSCOPIC CANCER CELLS. AMONG SYSTEMIC THERAPEUTICS, IMMUNOTHERAPY HAS THE POTENTIAL TO BE INTEGRATED WITH RT TO INDUCE A TUMOR-SPECIFIC IMMUNE RESPONSE THAT COULD ENABLE THE BODY'S OWN IMMUNE SYSTEM TO TARGET RESIDUAL AND METASTATIC TUMOR CELLS THAT ARE NOT ABLATED AFTER RADIATION THERAPY ALONE. SINCE RADIATION THERAPY RESULTS IN THE RELEASE OF TUMOR ASSOCIATED ANTIGENS FROM THE DYING TUMOR CELLS, INCREASING THE NUMBER AND ACTIVITY OF PROFESSIONAL ANTIGEN PRESENTING CELLS SUCH AS DENDRITIC CELLS COULD INCREASE THE INDUCTION OF EFFECTIVE TUMOR IMMUNITY. WE HAVE SHOWN THAT ADMINISTRATION OF FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L) SIGNIFICANTLY INCREASES IN THE NUMBER OF DENDRITIC CELLS AND SYNERGIZES WITH RADIATION THERAPY TO IMPROVE SURVIVAL IN PRECLINICAL MODELS OF LUNG CANCER AND IN PRELIMINARY RESULTS FROM A PILOT HUMAN TRIAL OF PATIENTS WITH NON-SMALL CELL LUNG CANCER. THIS PROPOSAL AIMS TO BROADEN THESE EXCITING FINDINGS BY EXPANDING THE CLINICAL EXPERIENCE TO MOVE THE THERAPY TOWARDS COMMERCIALIZATION FOR GREATER PATIENT ACCESS. THE PROPOSAL ALSO INCLUDES INTRODUCTION INTO THE CLINICAL TRIAL OF A DENDRITIC CELL ACTIVATING ANTIBODY THAT TARGETS CD40, A PATHWAY THAT HAS BEEN SHOWN TO SYNERGIZE WITH FLT3L AND RADIATION THERAPY. TO SUPPORT THE CLINICAL STUDY, CLINICAL GRADE FLTR3L AND THE CD40 AGONIST ANTIBODY WILL BE MANUFACTURED.
$0
8/11/22
Not listed
IMMUNE MODULATION OF RADIATION THERAPY WITH FLT3 LIGAND - PROJECT SUMMARY THIS PROPOSAL IS A UNIQUE COLLABORATION BETWEEN A SMALL, BUT FULL CAPABILITY BIOTECHNOLOGY COMPANY AND AN ACADEMIC INSTITUTION SPECIALIZED IN RADIATION THERAPY. STEREOTACTIC RADIOSURGERY (SRS) IS BEING FREQUENTLY USED TO CONTROL MACROSCOPIC TUMOR IN PATIENTS WITH LIMITED METASTASES. THE SUCCESS OF SRS IN CONTROLLING MACROSCOPIC DISEASE HAS GENERATED ENTHUSIASM IN COMBINING SRS WITH SYSTEMIC AGENTS, SUCH AS, CYTOTOXIC CHEMOTHERAPEUTICS AND BIOLOGICALLY TARGETED AGENTS FOR THE TREATMENT OF EARLY METASTATIC CANCER. THE GOAL IS TO TREAT MACROSCOPIC TUMOR WITH SRS WHILE SYSTEMIC CHEMOTHERAPY TARGETS MICROSCOPIC CANCER CELLS. AMONG SYSTEMIC THERAPEUTICS, IMMUNOTHERAPY HAS THE POTENTIAL TO BE INTEGRATED WITH RT TO INDUCE A TUMOR-SPECIFIC IMMUNE RESPONSE THAT COULD ENABLE THE BODY'S OWN IMMUNE SYSTEM TO TARGET RESIDUAL AND METASTATIC TUMOR CELLS THAT ARE NOT ABLATED AFTER RADIATION THERAPY ALONE. SINCE RADIATION THERAPY RESULTS IN THE RELEASE OF TUMOR ASSOCIATED ANTIGENS FROM THE DYING TUMOR CELLS, INCREASING THE NUMBER AND ACTIVITY OF PROFESSIONAL ANTIGEN PRESENTING CELLS SUCH AS DENDRITIC CELLS COULD INCREASE THE INDUCTION OF EFFECTIVE TUMOR IMMUNITY. WE HAVE SHOWN THAT ADMINISTRATION OF FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L) SIGNIFICANTLY INCREASES IN THE NUMBER OF DENDRITIC CELLS AND SYNERGIZES WITH RADIATION THERAPY TO IMPROVE SURVIVAL IN PRECLINICAL MODELS OF LUNG CANCER AND IN PRELIMINARY RESULTS FROM A PILOT HUMAN TRIAL OF PATIENTS WITH NON-SMALL CELL LUNG CANCER. THIS PROPOSAL AIMS TO BROADEN THESE EXCITING FINDINGS BY EXPANDING THE CLINICAL EXPERIENCE TO MOVE THE THERAPY TOWARDS COMMERCIALIZATION FOR GREATER PATIENT ACCESS. THE PROPOSAL ALSO INCLUDES INTRODUCTION INTO THE CLINICAL TRIAL OF A DENDRITIC CELL ACTIVATING ANTIBODY THAT TARGETS CD40, A PATHWAY THAT HAS BEEN SHOWN TO SYNERGIZE WITH FLT3L AND RADIATION THERAPY. TO SUPPORT THE CLINICAL STUDY, CLINICAL GRADE FLTR3L AND THE CD40 AGONIST ANTIBODY WILL BE MANUFACTURED.
$0
8/11/22
Not listed
IMMUNE MODULATION OF RADIATION THERAPY WITH FLT3 LIGAND - PROJECT SUMMARY THIS PROPOSAL IS A UNIQUE COLLABORATION BETWEEN A SMALL, BUT FULL CAPABILITY BIOTECHNOLOGY COMPANY AND AN ACADEMIC INSTITUTION SPECIALIZED IN RADIATION THERAPY. STEREOTACTIC RADIOSURGERY (SRS) IS BEING FREQUENTLY USED TO CONTROL MACROSCOPIC TUMOR IN PATIENTS WITH LIMITED METASTASES. THE SUCCESS OF SRS IN CONTROLLING MACROSCOPIC DISEASE HAS GENERATED ENTHUSIASM IN COMBINING SRS WITH SYSTEMIC AGENTS, SUCH AS, CYTOTOXIC CHEMOTHERAPEUTICS AND BIOLOGICALLY TARGETED AGENTS FOR THE TREATMENT OF EARLY METASTATIC CANCER. THE GOAL IS TO TREAT MACROSCOPIC TUMOR WITH SRS WHILE SYSTEMIC CHEMOTHERAPY TARGETS MICROSCOPIC CANCER CELLS. AMONG SYSTEMIC THERAPEUTICS, IMMUNOTHERAPY HAS THE POTENTIAL TO BE INTEGRATED WITH RT TO INDUCE A TUMOR-SPECIFIC IMMUNE RESPONSE THAT COULD ENABLE THE BODY'S OWN IMMUNE SYSTEM TO TARGET RESIDUAL AND METASTATIC TUMOR CELLS THAT ARE NOT ABLATED AFTER RADIATION THERAPY ALONE. SINCE RADIATION THERAPY RESULTS IN THE RELEASE OF TUMOR ASSOCIATED ANTIGENS FROM THE DYING TUMOR CELLS, INCREASING THE NUMBER AND ACTIVITY OF PROFESSIONAL ANTIGEN PRESENTING CELLS SUCH AS DENDRITIC CELLS COULD INCREASE THE INDUCTION OF EFFECTIVE TUMOR IMMUNITY. WE HAVE SHOWN THAT ADMINISTRATION OF FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L) SIGNIFICANTLY INCREASES IN THE NUMBER OF DENDRITIC CELLS AND SYNERGIZES WITH RADIATION THERAPY TO IMPROVE SURVIVAL IN PRECLINICAL MODELS OF LUNG CANCER AND IN PRELIMINARY RESULTS FROM A PILOT HUMAN TRIAL OF PATIENTS WITH NON-SMALL CELL LUNG CANCER. THIS PROPOSAL AIMS TO BROADEN THESE EXCITING FINDINGS BY EXPANDING THE CLINICAL EXPERIENCE TO MOVE THE THERAPY TOWARDS COMMERCIALIZATION FOR GREATER PATIENT ACCESS. THE PROPOSAL ALSO INCLUDES INTRODUCTION INTO THE CLINICAL TRIAL OF A DENDRITIC CELL ACTIVATING ANTIBODY THAT TARGETS CD40, A PATHWAY THAT HAS BEEN SHOWN TO SYNERGIZE WITH FLT3L AND RADIATION THERAPY. TO SUPPORT THE CLINICAL STUDY, CLINICAL GRADE FLTR3L AND THE CD40 AGONIST ANTIBODY WILL BE MANUFACTURED.
$0
8/11/22
Not listed
IMMUNE MODULATION OF RADIATION THERAPY WITH FLT3 LIGAND - PROJECT SUMMARY THIS PROPOSAL IS A UNIQUE COLLABORATION BETWEEN A SMALL, BUT FULL CAPABILITY BIOTECHNOLOGY COMPANY AND AN ACADEMIC INSTITUTION SPECIALIZED IN RADIATION THERAPY. STEREOTACTIC RADIOSURGERY (SRS) IS BEING FREQUENTLY USED TO CONTROL MACROSCOPIC TUMOR IN PATIENTS WITH LIMITED METASTASES. THE SUCCESS OF SRS IN CONTROLLING MACROSCOPIC DISEASE HAS GENERATED ENTHUSIASM IN COMBINING SRS WITH SYSTEMIC AGENTS, SUCH AS, CYTOTOXIC CHEMOTHERAPEUTICS AND BIOLOGICALLY TARGETED AGENTS FOR THE TREATMENT OF EARLY METASTATIC CANCER. THE GOAL IS TO TREAT MACROSCOPIC TUMOR WITH SRS WHILE SYSTEMIC CHEMOTHERAPY TARGETS MICROSCOPIC CANCER CELLS. AMONG SYSTEMIC THERAPEUTICS, IMMUNOTHERAPY HAS THE POTENTIAL TO BE INTEGRATED WITH RT TO INDUCE A TUMOR-SPECIFIC IMMUNE RESPONSE THAT COULD ENABLE THE BODY'S OWN IMMUNE SYSTEM TO TARGET RESIDUAL AND METASTATIC TUMOR CELLS THAT ARE NOT ABLATED AFTER RADIATION THERAPY ALONE. SINCE RADIATION THERAPY RESULTS IN THE RELEASE OF TUMOR ASSOCIATED ANTIGENS FROM THE DYING TUMOR CELLS, INCREASING THE NUMBER AND ACTIVITY OF PROFESSIONAL ANTIGEN PRESENTING CELLS SUCH AS DENDRITIC CELLS COULD INCREASE THE INDUCTION OF EFFECTIVE TUMOR IMMUNITY. WE HAVE SHOWN THAT ADMINISTRATION OF FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L) SIGNIFICANTLY INCREASES IN THE NUMBER OF DENDRITIC CELLS AND SYNERGIZES WITH RADIATION THERAPY TO IMPROVE SURVIVAL IN PRECLINICAL MODELS OF LUNG CANCER AND IN PRELIMINARY RESULTS FROM A PILOT HUMAN TRIAL OF PATIENTS WITH NON-SMALL CELL LUNG CANCER. THIS PROPOSAL AIMS TO BROADEN THESE EXCITING FINDINGS BY EXPANDING THE CLINICAL EXPERIENCE TO MOVE THE THERAPY TOWARDS COMMERCIALIZATION FOR GREATER PATIENT ACCESS. THE PROPOSAL ALSO INCLUDES INTRODUCTION INTO THE CLINICAL TRIAL OF A DENDRITIC CELL ACTIVATING ANTIBODY THAT TARGETS CD40, A PATHWAY THAT HAS BEEN SHOWN TO SYNERGIZE WITH FLT3L AND RADIATION THERAPY. TO SUPPORT THE CLINICAL STUDY, CLINICAL GRADE FLTR3L AND THE CD40 AGONIST ANTIBODY WILL BE MANUFACTURED.
$1.6m
8/26/21